Press Release
본문 바로가기
메인메뉴
Company
About Qurient
History
Management
Contact Us
Business Philosophy
Pipeline
Pipeline
Adrixetinib (Q702)
Q901
Q301
Telacebec (Q203)
5-Lipoxygenase Inhibitor
Clinical Trials
Clinical Trials
IR / PR
Notice
Press Release
Qurient in the news
Financial
Disclosure
Blog
WEBTOON
WEBTOON
Company
Pipeline
Clinical Trials
IR / PR
WEBTOON
Notice
Press Release
Qurient in the news
Financial
Disclosure
Blog
Press Release
큐리언트, 400억 원 규모 유상증자 결정
페이지 정보
Author
QURIENT
Date
2019-04-03 13:53
Views
2,763
본문
Prev
Next
List
information for download file
* Name
Company
Phone
* Business e-mail
Comment
Request Download
팝업 닫기
Press Release